Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory drug (IMiD) presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across markets.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic clones. Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. Mantle Cell Lymphoma: achieves disease control and prolongs remission in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia - Thrombocytopenia - Fatigue - Nausea

Serious or Rare Side Effects: - Venous thromboembolism - Severe infections associated with profound neutropenia - Secondary primary malignancies - Hypersensitivity reactions

Before initiating therapy, several safety considerations should be reviewed. Pregnancy: contraindicated due to known teratogenicity. Breastfeeding: not recommended; avoid during lactation. Blood count monitoring: perform regular complete blood counts to detect cytopenias. Thromboembolic risk: assess need for prophylactic anticoagulation in high‑risk patients. Renal impairment: dose adjustment may be required based on renal function. Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Live vaccines: risk of uncontrolled infection. - Strong CYP inducers (e.g., rifampicin): may reduce lenalidomide exposure. - Hormonal contraceptives: reduced effectiveness, consider alternative contraception.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations. - NSAIDs: can exacerbate cytopenias. - Diuretics: may affect renal clearance of the drug. - Immunosuppressants: heightened risk of opportunistic infections.